$73.73+2.86 (+4.04%)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
PTC Therapeutics, Inc. in the Healthcare sector is trading at $73.73. Wall Street consensus targets $93.93 (14 analysts), implying a +27.4% move over the next 12 months. The stock is currently 16% below its 52-week high of $87.50, remaining 6.3% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna...
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
PTC Therapeutics just saw its fair value estimate move from US$90.93 to US$91.57, a small shift that still matters if you are tracking how the story is evolving. That change sits against a split backdrop of analyst commentary, with some firms lifting ratings or targets on the back of Sephience assumptions while others are trimming or holding steady. As you read on, you will see how these different views shape the narrative you may want to follow over the coming months. Analyst Price Targets...
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.